Pfizer Inc. (PFE) is the 49th-largest public company in the world, according to Forbes. As of Feb. 4, 2021, Pfizer had a market capitalization of $194 billion. Pfizer's roots date back to 1849, when two German-American entrepreneurs started the company as a fine chemicals business and grew it into a world-leading pharmaceuticals company that manufactures, markets, and distributes over 312 drugs in the United States.

In 2018, Pfizer came under scrutiny for raising the prices of 100 of the company's drugs. That July, Donald Trump also singled out Pfizer in a tweet, claiming that the company is "merely taking advantage of the poor & others unable to defend themselves." Donald Trump's Twitter account was permanently suspended in Jan. 2021.

In December 2020, Pfizer's COVID-19 vaccine was granted emergency use authorization by the Food and Drug Administration.

Important

On Nov. 9, 2020, Pfizer and BioNTech announced that trial results showed their vaccine to be more than 90% effective in preventing COVID-19 among those with no evidence of prior infection.

Although many people are familiar with Pfizer and may use the company's products, they may not be familiar with these interesting facts.

Key Takeaways:

  • Pfizer is the 49th-largest public company in the world, with a market capitalization of $194 billion as of February 2021.
  • Founded in 1849 by two German-American entrepreneurs, Pfizer has expanded its reach from its first antiparasitic drug used to treat intestinal worms to a host of consumer products, including citric acid, used in many soft drinks.
  • Over the years, Pfizer has been no stranger to controversy, from lawsuits alleging trade secret theft to the millions of dollars it spends on lobbying.

1. Pfizer Started in Brooklyn, New York

Cousins Charles Pfizer and Charles Erhart started Pfizer in the 1800s with $2,500 that Pfizer borrowed from his father. The cousins used the loan to open the chemicals business under the name of Charles Pfizer & Company. Pfizer operated in a red brick building located in Williamsburg, a neighborhood in Brooklyn, New York. The modest building served as Pfizer's laboratory, factory, warehouse, and office. Today, Pfizer headquarters are still based in New York City.

2. Pfizer's First Products and Innovation

Pfizer formulated its first product in 1849, an antiparasitic drug used to treat intestinal worms during the 1800s. Chemist Pfizer and confectioner Erhart naturally blended santonin with flavoring and shaped it into a candy cone. Pfizer launched the first domestic production of cream of tartar and tartaric acid, ingredients used heavily in the food and chemical industries. Pfizer expanded the production of tartaric acid and cream of tartar during the Civil War to support the Union Army.

3. Pfizer and Citric Acid

Pfizer began manufacturing citric acid using concentrates of lime and lemon in 1880. As soft drinks, such as those produced by The Coca-Cola Company (KO), Keurig Dr. Pepper Inc. (KDP), and PepsiCo Incorporated (PEP), used citric acid in their formulas, the demand for the biochemical grew. Thereafter, Pfizer's main product and growth stemmed from citric acid.

4. Pfizer's Shift in Ownership and Incorporation

Erhart died on Dec. 27, 1891, and he left his partnership, worth $250,000, to his son William Erhart. However, the agreement stated that Pfizer had the option to purchase William Erhart's stake at 50% of the inventory. Pfizer exercised his option and became the sole owner of the company. Nine years later, Pfizer filed a certificate of incorporation in New Jersey with 20,000 shares issued at par value, or $100 per share. However, Charles Pfizer & Company remained a privately held company until 1942, when it issued 240,000 shares of common stock to the general public.

5. Pfizer Stealing Drug Secrets

Nonprofit Ischemia Research and Education Foundation filed a lawsuit against Pfizer in 2004, which alleged that Pfizer arranged a deal with lead statistician Ping Hsu at the Ischemia Research and Education Foundation to provide data. Additionally, the research foundation alleged that Pfizer stole trade secrets to develop Bextra, a pain medication. Pfizer and Hsu destroyed evidence that could have proven they stole trade secrets and used data without approval when the foundation confronted the two. On Dec. 24, 2008, a Santa Clara County jury ordered Pfizer to pay $38 million to the Ischemia Research and Education Foundation for stealing drug secrets.

6. Pfizer's Lobbying Expenses

Pfizer is one of the top pharmaceutical lobbying spenders and spends money lobbying for corporate tax cuts, among other political topics. According to a study in JAMA Internal Medicine, Pfizer spent $219 million in lobbying expenses and $23 million in campaign contributions between 1999 and 2018. Though Pfizer's lobby expenses are primarily spent on health and tax issues, in 2015 and 2016, its primary focus was on tax issues as the company promoted the U.S. tax reform.

7. Pfizer's Acquisitions and Mergers

Pfizer made its first acquisition in 1953 and took over J.B. Roerig & Company, which specialized in nutritional supplements. J.B. Roerig became a division of the company and still plays an integral role in Pfizer's marketing segment. In 1955, Pfizer partnered with Japanese drug company Taito to manufacture and distribute antibiotics. Nearly 30 years after the partnership, Pfizer acquired full ownership of Taito. Pfizer also acquired Mack Illertissen, a German pharmaceutical, chemical, and consumer products company that focused on the needs of German consumers.

Pfizer acquired Warner-Lambert in 2000 for over $90 billion, bringing together two of the fastest-growing pharmaceutical companies at the time. That deal grew Pfizer's global presence significantly and increased its product line, which now includes popular pharmaceutical products such as Listerine mouthwash. Pfizer's most recent acquisition was a deal to buy Array BioPharma Inc. for $48 per share in cash. According to a Pfizer press release, Array BioPharma is "advancing breakthrough science for the discovery, development, and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need."